Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Terns Pharmaceuticals (TERN) Gains from Investment Securities (2021 - 2023)

Historic Gains from Investment Securities for Terns Pharmaceuticals (TERN) over the last 3 years, with Q3 2023 value amounting to $65000.0.

  • Terns Pharmaceuticals' Gains from Investment Securities fell 2613.64% to $65000.0 in Q3 2023 from the same period last year, while for Dec 2023 it was $65000.0, marking a year-over-year decrease of 9592.48%. This contributed to the annual value of $1.3 million for FY2024, which is 190307.69% up from last year.
  • According to the latest figures from Q3 2023, Terns Pharmaceuticals' Gains from Investment Securities is $65000.0, which was down 2613.64% from -$6000.0 recorded in Q4 2022.
  • Over the past 5 years, Terns Pharmaceuticals' Gains from Investment Securities peaked at $3.6 million during Q3 2021, and registered a low of -$6000.0 during Q4 2022.
  • Moreover, its 3-year median value for Gains from Investment Securities was $875500.0 (2021), whereas its average is $1.3 million.
  • As far as peak fluctuations go, Terns Pharmaceuticals' Gains from Investment Securities tumbled by 10252.1% in 2022, and later plummeted by 2613.64% in 2023.
  • Terns Pharmaceuticals' Gains from Investment Securities (Quarter) stood at $238000.0 in 2021, then crashed by 102.52% to -$6000.0 in 2022, then surged by 1183.33% to $65000.0 in 2023.
  • Its Gains from Investment Securities stands at $65000.0 for Q3 2023, versus -$6000.0 for Q4 2022 and $88000.0 for Q3 2022.